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Abstract
Background Although stent placement is increasingly
performed, colostomy still is considered the gold standard
for emergent relief of malignant colonic obstruction
(MCO). This study aimed to compare hospital costs and
clinical outcomes between patients undergoing colostomy
and those undergoing stenting for the management of
MCO.
Methods A retrospective claims analysis of the Medicare
Provider Analysis and Review (MedPAR) data set was
conducted to identify inpatient hospitalizations for colos-
tomy or stent placement for the treatment of colon cancer
(2007–2008). The outcomes evaluated using MedPAR
compared the total length of hospital stay (LOS) and the
costs associated with both techniques. Because MedPAR is
a claims data set that does not provide outcomes at a
patient level, a single-institution retrospective case–control
study was conducted in which each stent placement patient
was matched with two colostomy patients during the same
period. Outcome measures (institutional data) were used to
compare rates of treatment success, postprocedure LOS,
and reinterventions between the two cohorts.
Results The MedPAR data evaluated 778 stent place-
ments and 5,868 colostomy hospitalizations. There were no
differences in gender, age distribution, or comorbidity
between the two groups. Compared with colostomy, the
median LOS (8 vs. 12 days; p\0.0001) and the median
cost ($15,071 vs. $24,695; p\0.001) per claim were
signiﬁcantly less for stent placement. Stent placement was
more commonly performed at urban versus rural hospitals
(84% vs. 16%; p\0.0001), teaching versus nonteaching
hospitals (56% vs. 44%; p = 0.0058) and larger versus
smaller institutions (mean bed capacity, 331 vs. 227;
p\0.0001). The institution data included 12 patients who
underwent stent placement and 24 who underwent colos-
tomy. Although both methods were technically successful,
the median postprocedure LOS (2.17 vs. 10.58 days;
p = 0.0004) and the rate of readmissions for complications
(0% vs. 25%; p = 0.01) were signiﬁcantly lower for stent
placement.
Conclusion Although the technical and clinical outcomes
for colostomy and stent placement appear comparable,
stent placement is less costly and associated with shorter
LOS and fewer complications. Dissemination of stent
placement beyond large teaching hospitals located in urban
areas as a treatment for MCO is important given its
implications for patient care and resource use.
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Approximately 8% to 29% of patients with colorectal
cancer present with acute malignant colonic obstruction
(MCO) [1]. Although surgical decompression is the stan-
dard of care, the rates for mortality (15–20%) and mor-
bidity (45–50%) in this context are signiﬁcantly higher
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addition, curative resection is not possible for one-third of
the patients presenting with acute MCO due to locally
advanced disease, distant metastasis, or severe comorbidi-
ties [4].
Therefore, the traditional management approach is an
emergency open surgery to relieve the obstruction and
resect the tumor. Many patients, particularly those with
obstructing left-sided colon cancer, end up with temporary
or permanent stomas, which can adversely affect their
health-related quality of life [5, 6].
Numerous studies have shown that self-expandable
metal stent (SEMS) placement is a relatively simple and
safe alternative to standard surgical management because it
obviates the need for emergency surgery or colostomy
[7, 8]. In a pooled analysis of SEMS, the rates of technical
success and clinical effectiveness for relief of acute MCO
were reported to be greater than 90% [9]. The procedure is
effective both for palliation in patients with inoperable
disease and for temporary preoperative decompression
(bridge to surgery) in surgical candidates [10].
In a randomized trial that included 48 patients with
obstructive left-sided colon cancer, 67% of the patients
who underwent endolaparoscopic surgery (colonic stent-
ing followed by elective laparoscopic resection) had
successful one-stage operations compared with only 38%
of the patients who underwent emergent open surgery
[11]. Nevertheless, a SEMS is expensive, and it is
unclear whether its use is cost effective compared with
colostomy. Conclusions from computer-assisted decision
analyses and direct-cost European studies have been
conﬂicting [12–17]. Because all clinical studies were
from single centers and included a small cohort of
patients, the general applicability of these data is
debatable.
The objectives of the current study were to compare the
hospital costs and hospital length of stay (LOS) at a
national level by using a claims database and to compare
the clinical outcomes at a patient level by conducting a
single-institution retrospective case–control study for
patients undergoing colostomy versus stenting for man-
agement of MCO.
Materials and methods
This study was executed in two parts. First, MedPAR data
was used to evaluate hospital costs and the LOS for
patients who underwent colostomy or stenting for MCO.
Second, because clinical outcomes, except for LOS, cannot
be evaluated using MedPAR, a retrospective case–control
study was conducted to evaluate patient outcomes at an
institutional level.
MedPAR data source
A retrospective analysis was conducted using the
2007–2008 MedPAR data. The MedPAR database contains
complete inpatient hospitalization records for the entire
U.S. Medicare population, or 36.8 million covered lives.
These claims report patient demographic information such
as age, sex, diagnosis, and comorbidities. In addition,
information regarding the hospitalization is provided
including LOS, diagnostic testing, therapeutic procedures,
and the charge for each hospitalization. The MedPAR data
set also provides geographic and demographic information
for the hospitals in which those claims were generated
including location, associations, teaching status, number of
beds, and number of full-time employees.
Patient population
The study population consisted of all unique hospitaliza-
tion claims for the placement of a colonic stent or for a
colostomy procedure. Claims were included based on pri-
mary diagnosis and procedure. In 2007 and 2008, no
unique International Classiﬁcation of Diseases (ICD-9-
CM) code was in place for reporting colonic stent place-
ment. As such, the following proxy was developed to
identify claims: a colorectal cancer diagnosis with any one
of the following ICD-9-CM diagnosis codes: 153.0–153.3,
153.6–154.1 reported with any one of the following
endoscopy ICD-9-CM codes: 45.22, 46.79, 46.85 reported
with revenue code 0278: medical/surgical supplies other
implant. Colostomy claims were identiﬁed by a colorectal
cancer diagnosis reported with any one of the following
surgical resection ICD-9-CM codes: 45.73–45.80 reported
with any one of the following colostomy ICD-9-CM codes:
46.03, 46.10–46.11, 46.13. Claims that had both stent
placement and colostomy reported together were excluded
from the analysis.
Outcome measures
The outcomes evaluated compared the total hospitalization
costs and the total LOS associated with each technique.
Using the Medicare Cost Report, the hospitalization costs
were derived by applying the cost-to-charge ratio to the
reported charges in MedPAR. A secondary analysis also
was conducted to analyze the demographics of the hospi-
tals in which the procedures were performed.
Institutional data
Because MedPAR is a claims database that does not pro-
vide outcomes at a patient level, a single-institution retro-
spective case–control study was conducted in which each
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123patient who underwent a stent placement was matched with
two colostomy patients during the same period
(2007–2008).
Patient population
A retrospective analysis was conducted with consecutive
patients ([19 years of age) who underwent surgical
diversion or colorectal stenting for management of acute
MCO. Patients were identiﬁed from the endoscopy and
surgery databases. The inclusion criteria speciﬁed patients
older than 19 years with an underlying diagnosis of colo-
rectal cancer who had undergone procedures for relief of
acute obstruction. The exclusion criteria ruled out patients
who had undergone colostomy or stenting for benign dis-
eases or colostomy for perforated colon cancer.
For each patient treated with colonic stents, two patients
who underwent emergency surgery (cancer resection with
colostomy) for acute MCO were matched by an indepen-
dent observer for the following variables: location of can-
cer, cancer stage, and presence of distant metastasis. The
independent observer who conducted the matching process
was blinded to all clinical outcomes and costs. The medical
records of all the study subjects were reviewed for patient
demographics, clinical presentation, comorbidities, labo-
ratory investigations, site of large bowel obstruction, can-
cer staging, and radiologic investigations.
Colonic stenting
Each SEMS (Ultraﬂex Precision; Boston Scientiﬁc Corp,
Natick, MA, USA) was deployed under ﬂuoroscopic
guidance with the patient in the left lateral position using a
combination of intravenous midazolam and meperidine
(Video 1). The stents measured 25 mm in the body and
30 mm in the proximal ﬂare and were 6, 9, or 12 cm in
length.
At colonoscopy, a 0.035-in. guidewire was ﬁrst
advanced across the stricture. A 5-Fr endoscopic retrograde
cholangiopancreatography (ERCP) cannula then was
advanced over the guidewire, and contrast was injected to
assess the length of the stricture. The SEMS delivery sys-
tem then was advanced over the guidewire, and after sat-
isfactory positioning of the delivery catheter had been
conﬁrmed by ﬂuoroscopy, the SEMS was deployed.
Surgical resection and colostomy (Hartman’s procedure)
Brieﬂy, after a midline incision had been performed, the
obstructive tumor was resected and the proximal colon
externalized as a colostomy. The rectal stump was sealed
with surgical staples during the resection.
Outcome measures
The rates for treatment success, complications, and rein-
terventions were compared as well as the length of the
postprocedure hospital stay between each treatment
method.
Consent
All the patients provided informed consent for undergoing
the procedures, and the study was approved by the Uni-




All analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC, USA). Discrete data are reported as
frequencies and continuous data as median and mean.
Using a chi-square test, the patient demographics and
comorbidities reported on the claims were compared across
the stenting and colostomy cohorts. Covariates were not
adjusted for in the analysis of health resources due to
constraints of using MedPAR data.
Institutional data
Statistical analysis was performed using Stata 9.2 (Stata-
Corp LP, College Station, TX, USA). Patient demographics
and disease characteristics were compared across the two
groups (SEMS and surgery). A two-sample t-test was used
to compare the means of the continuous variables such as
age, albumin levels, and Charlson’s score. A chi-square test
was used to compare the proportions of disease charac-




A total of 778 colonic stent placements and 5,868 colos-
tomy claims met the criteria for inclusion in the study. The
age, gender, and comorbidities of the reported patients in
both cohorts are shown in Table 3. The colostomy cohort
had more reported women than the stenting cohort. Except
for liver disease and diabetes, the two cohorts did not differ
signiﬁcantly in terms of comorbid conditions.
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The median aggregate hospital days or the total LOS from
admission to discharge was 8 days for colonic stent
placement claims and 12 days for colostomy claims
(p\0.0001). The stent placement claims had signiﬁcantly
lower total median hospital costs per claim than the
colostomy claims. The mean hospital costs for the stent
placement cohort were $21,771 versus $33,383 for the
colostomy cohort (p\0.0001).
Stent placement was more commonly performed at
urban (84%) versus rural hospitals (16%) (p\0.0001) and
at teaching (56%) versus nonteaching (44%) institutions
(p\0.006). In addition, stent placement was more com-
monly performed at larger institutions with a mean
capacity of 331 beds than at smaller institutions with a
mean capacity of 227 beds for colostomy procedures
(p\0.0001).
Institutional data
The single-institution retrospective case–control study
involved 12 patients who underwent colonic stenting and
24 patients who underwent surgery for acute MCO. Two
SEMS patients were excluded because they returned to the
referring facility for further care after stent placement.
Neither of these excluded patients experienced any intra-
procedural complications.
After each SEMS patient had been matched with two
patients who had undergone surgery, the study cohort
comprised of a total of 36 patients. Table 1 displays the
demographics and disease characteristics of all the patients
at presentation. The two cohorts did not differ signiﬁcantly
in terms of patient demographics, tumor characteristics, or
comorbidities.
Colostomy and SEMS placements were successful in
relieving the obstruction in all the patients. Whereas the
mean postprocedure LOS was signiﬁcantly shorter (2.17
vs. 10.58 days; p = 0.004), there was no signiﬁcant dif-
ference in the preprocedure LOS between the patients who
underwent SEMS placements (1 day) and those that had
colostomy (1.4 days) (p = 0.72).
One SEMS patient experienced self-limited lower gas-
trointestinal bleeding during the initial hospitalization that
did not require reintervention or blood transfusion, whereas
eight patients (33%) in the surgery group experienced
complications (8.3% vs. 33.3%; p = 0.08) including sepsis
(n = 1), parastomal hernia (n = 1), anastomotic leak
(n = 1), peristomal abscess (n = 1), intraabdominal
abscess (n = 1), small bowel obstruction (n = 1), entero-
cutaneous ﬁstula (n = 1), and pelvic abscess (n = 1).
Whereas none of the patients who underwent SEMS
placement required a readmission for stent-related com-
plications, six patients who underwent surgery required
readmission for complications (0% vs. 25%, p = 0.019).
One patient (4%) in the surgical cohort died of sepsis
28 days after undergoing colostomy.
Of the 12 patients who underwent SEMS placements, 6
had elective one-stage operations for tumor resection. The
remaining six 6 patients were treated palliatively. At the









Mean age (year) 67.08 58.25 0.052
Gender (% female) 50 54.1 0.813
Race (% African American) 33.33 45.83 0.469
Cancer site: n (%) 1.000
Sigmoid 9 (75) 18 (75)
Rectum 2 (17) 4 (17)
Transverse 1 (8) 2 (8)
Histology: n (%) (adenocarcinoma) 12 (100) 24 (100) 1.000
Stage: n (%) 0.655
2 2 (17) 4 (17)
3 1 (8) 5 (21)
4 9 (75) 15 (62)
Metastasis: n (%) 10 (83) 15 (63) 0.186
Mean albumin (mg/dl) 3.10 2.69 0.212
Mean Charlson’s score 6.08 5.54 0.426










n (%) n (%)
Technical success 12 (100) 24 (100) 1.000
Clinical success 12 (100) 24 (100) 1.000
Intraprocedure complication 0 (0) 0 (0) 1.000
Delayed complication 1 (8.3) 8 (33.3) 0.081
Readmittance for complication 0 (0) 6 (25) 0.019
Mean postprocedure hospital stay (days) 2.17 10.58 0.004
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123last follow-up visit, only two of six patients who underwent
elective resections were alive. The others had died of
metastatic cancer or some other comorbidity. Of the six
patients who underwent palliative stenting, follow-up data
were available for four who died without requiring any
reinterventions. The two remaining patients had died but
were lost to follow-up evaluation after stent placement.
Of the 24 patients who had colostomy, 5 underwent
surgical reanastomosis and were alive at a median follow-
up time of 29 months (range, 13–46 months). Of the
remaining 19 patients, 14 had died, 3 were receiving pal-
liative therapy, and 2 were lost to follow-up evaluation.
Discussion
Colonic stenting is an effective alternative to surgery for
both palliation and conversion of an emergent operation to
an elective surgery. Three decision analyses and two case
series, mostly from Canada and Europe, have attempted to
address the cost effectiveness of the colonic stent approach
[12–16]. In one decision analysis, colonic stenting was
found to be more expensive than diverting colostomy, and
in two others, stent placement was less costly than surgery,
whether performed as resection with colostomy or as pri-
mary resection with anastomosis [12–14].
In the two case series, colon stenting was found to be
more expensive than colostomy in the one series [15] and
less expensive than surgical resection in the other [16]. The
reason for this may be that diverting loop colostomy is
performed as a palliative procedure through a smaller
incision and is not as extensive an operation as resection
and end colostomy. Although modeling is useful for
comparison of costs and outcomes between different
methods, the results are not expected to be precise because
predictions are dependent on the accuracy of clinical out-
come probabilities, many of which are unknown. Thus, the
diverging results achieved by the aforementioned studies
are not surprising.
In the current study, the median cost per claim was
$9,600 lower for patients undergoing SEMS placement.
These ﬁndings involving 778 SEMS and 5,868 surgical
claims are more realistic for the costs involving both
treatment methods in the United States’ population.
In a metaanalysis of 10 studies, the LOS was shorter by
8 days for the patients who underwent colon stenting than
for those who underwent surgery [17]. However, this
ﬁnding was associated with signiﬁcant heterogeneity. In
the current study, the median LOS per claim was shorter by
4 days for the patients who underwent stenting than for the
surgical cohort. Whereas the total LOS can be estimated
using the MedPAR database, it is not possible to assess the
postprocedure LOS. When these clinical outcomes were
evaluated at an institutional level, the postprocedure LOS
was shorter by 8 days for patients who underwent colonic
stenting.
Whereas 6 of 12 patients in the SEMS cohort underwent
successful one-stage elective surgery, only 5 of 24 patients
in the surgical cohort underwent reanastomosis at a later
time. This is in line with the ﬁndings of a recent random-
ized trial in which a majority of patients who underwent
emergency surgery for acute MCO had a permanent stoma
[11]. Whereas no signiﬁcant complication occurred in the
SEMS group, eight patients in the surgery group experi-
enced complications, and six patients required a readmis-
sion. Even in the absence of complications, surgical
patients required lengthier postprocedure hospital stays for
pain management, return of bowel function, and tolerance
of regular diet.
Our study had some limitations. Although it would have
been ideal to conduct a longitudinal study evaluating
the two cohorts from the initial procedure to death, track-
ing procedures performed and associated costs, one limi-
tation of the MedPAR claims database is the inability to
run a longitudinal analysis. There are no unique patient
Table 3 Baseline demographics and co-morbid conditions of the
stent placement and colostomy patient populations as reported in











25–44 1.0 0.3 0.001
45–64 8.4 6.6 0.061
65–69 17.5 16.0 0.304
70–74 19.4 16.5 0.042
75–79 17.9 19.2 0.359
80–84 15.8 19.0 0.030
85–89 10.2 13.8 0.005
[89 9.8 8.6 0.266
Female 45.6 52.2 0.001
Comorbid conditions
CHF 12.3 12.8 0.738
COPD 13.9 14.6 0.574
Cerebrovascular disease 2.8 3.0 0.852
Diabetes without complications 13.0 12.4 0.619
Diabetes with complications 0.3 1.0 0.034
Myocardial infarction 4.6 4.6 0.991
Moderate/severe liver disease 1.9 0.3 \0.0001
Peripheral vascular disease 3.6 3.0 0.362
Renal disease 7.3 5.7 0.075
CHF congestive heart failure, COPD chronic obstructive pulmonary
disease
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123identiﬁers to track the same patient over time. The Med-
PAR database allows only for cross-sectional studies to be
performed.
In addition, outcomes data, such as procedural success
and complications rates, cannot be evaluated using a
claims database. It also is possible that some of the patients
who underwent colostomy had failed attempts at prior stent
placement. At an institutional level, because patients were
not followed prospectively, it is likely that some minor
adverse events were not captured.
Despite rigorous matching, it is possible that outcomes
were inﬂuenced by the patient composition in each group.
However, this may not be a major limitation because
patients undergoing SEMS were older (67 vs. 58 years;
p = 0.052) and had marginally higher Charlson’s scores
(6.08 vs. 5.54; p = 0.426). With the exception of one
patient who underwent stenting of the transverse colon,
obstruction was limited to the left colon or rectum in all the
other patients. Moreover, every attempt was made to
maintain uniformity by matching both groups for site of
obstruction, cancer stage, and presence of distant metas-
tasis. Also, the Charlson’s comorbidity scores were com-
parable between the two groups.
In addition, this case–control study examined a small
sample of patients from a single institution. As a result, the
ability to generalize these ﬁndings to a national sample is
limited and is not the intent of this study. Because it was a
retrospective case–control study, we could not present data
on the rates of technical failure in the SEMS cohort or on
the number of patients who failed stent placement and
subsequently underwent surgery.
Analysis of the claims data showed that despite its
inherent clinical advantages and cost savings, colonic
stenting is more commonly performed at large urban
teaching hospitals. We speculate that in large teaching
institutions, better collaboration between the disciplines of
medical gastroenterology and general surgery result in
more patients undergoing SEMS placement in the emer-
gent setting. In smaller and rural hospitals, patients prob-
ably are managed by the manner in which they are triaged
at admission. Those admitted to the gastroenterology ser-
vice are more likely to undergo stent placement, and those
admitted to the surgical service are more likely to undergo
resection.
It is our opinion that at least for patients with multiple
comorbidity and poor functional status, colon stent place-
ment should be the favored initial treatment approach
because these patients are poor operative candidates and
unlikely to endure a second surgery for reanastomosis.
More education and training is needed to propagate the
appropriate use of stents in patients presenting with acute
MCO. Training in stent deployment should be incorporated
in general surgery residency programs by the use of
simulators or models, or by enabling residents to rotate in
the medical gastroenterology service.
In conclusion, although the technical and clinical out-
comes of colostomy and stent placement appear compara-
ble in relieving obstruction, stent placement is less costly
and associated with shorter LOS and fewer complications.
Dissemination of stent placement beyond large teaching
hospitals located in urban areas as a treatment for MCO is
important given its implications for patient care and
resource use.
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